以甲氨蝶呤为核心的类风湿关节炎的联合药物治疗
被引量:6
摘要
早期应用甲氨蝶呤(MTX)治疗RA,除了控制疾病炎症的活动性外,还可以延长RA患者的总体生存时间。研究发现:MTX不仅对炎症反应有抑制作用,还具有抗动脉粥样硬化作用。MTX能够促进动脉粥样硬化形成过程中动脉壁内泡沫细胞中胆固醇的流出。因此,MTX对类风湿关节炎(RA)患者生存时间的延长或许归功于其对心血管事件及关节外受累的有益作用。
出处
《中国医刊》
CAS
2013年第7期5-7,共3页
Chinese Journal of Medicine
参考文献14
-
1Reiss AB, Carsons SE, Anwar K, et al. Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages [ J ]. Arthritis Rheum ,2008,58:3675-3683.
-
2Rath T, Rubbert A. Drug combinations with methotrexate to treat rheumatoid arthritis[J]. Clin Exp Rheumatol,2010 ,28 :52-57.
-
3Rau R. Efficacy of methotrexate in comparison to biologics in rheu- matoid arthritis[J]. Clin Exp Rheumatol,2010 ,28 :58-64.
-
4Keystone E, Heijde D, Mason D Jr,et al. Certolizumab pegol plus methotrexate is significandy more effective than placebo plus metho- trexate in active rheumatoid arthritis: findings of a fifty-two-week, Phase Ⅲ, muhicenter, randomized, double-blind, placebo-controlled, parallel-group study [ J ]. Arthritis Rheum, 2008, 58 : 3319-3329.
-
5Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell= targeted therapy with rituximab in patients with rheumatoid arthritis [J]. N Engl J Med,2004,350:2572-2581.
-
6Kremer JM, Genant HK, Moreland LW,et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial[J]. Ann Intern Med,2006,144:865-876.
-
7Papagoras C, Voulgari PV, Dmsos AA. Strategies after the failure of the flint anti-tumor necrosis factor alpha agent in rheumatoid arthritis [ J]. Autoimmun Rev,2010,9:574-582.
-
8Visser K, Katchamart W, Loza E, et al. Multinational evidence- based recommendations for the use of methotrexate in rheumatic dis- orders with a focus on rheumatoid arthritis: integrating systematic lit- erature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative[ J]. Ann Rheum Dis,2009,68: 1086-1093.
-
9Yazici Y, Erkan D, Paget SA. Monitoring by rheumatologists for methotrexate, etanercept, infliximab, and anakinra-associated ad- verse events[J]. Arthritis Rheum,2003,48:2769-2772.
-
10Abasolo L, Jadez E, Descalzo MA,et al. Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a south Eu- ropean population[J]. Semin Arthritis Rheum,2008,37:388-397.
同被引文献92
-
1李军,张奉春.糖皮质激素在类风湿关节炎中的应用[J].中国医刊,2004,39(8):11-13. 被引量:3
-
2李立明,饶克勤,孔灵芝,姚崇华,向红丁,翟凤英,马冠生,杨晓光,中国居民营养与健康状况调查技术执行组.中国居民2002年营养与健康状况调查[J].中华流行病学杂志,2005,26(7):478-484. 被引量:1780
-
3中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5221
-
4菲尔斯坦.凯利风湿病学[M].粟占国,译.8版.北京:北京大学医学出版社.2011:1089.
-
5吴兆苏,姚崇华,赵冬,等.11 省市队列人群心血管病发病前瞻性研究Ⅱ.个体危险因素聚集与心血管病发病的关系[J].中华心血管病杂志,2001,29(4):246-250.
-
6Maradit-Kremers H, Nicola PJ, Crowson CS, et al. Cardiovascular death in rheumatoid arthritis: a population-based study [ J ]. Arthritis Rheum, 2005,52 (3) :722-732.
-
7van Halm VP, Peters M J, Voskuyl AE, et al. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross- sectional study, the CARRE Investigation [ J ]. Ann Rheum Dis, 2009,68 ( 9 ) : 1395-1400.
-
8Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence- based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis[J]. Ann Rheum Dis, 2010,69(2) :325-331.
-
9Cobb S, Anderson F, Bauer W. Length of life and cause of death in rheumatoid arthritis [ J ]. N Engl J Med, 1953,249 (14) :553-556.
-
10Chung CP, Giles JT, Petri M, et al. Prevalence of traditional modi- fiable cardiovascular risk factors in patients with rheumatoid arthri- tis: comparison with control subjects from the multi-ethnic study of atheroselerosis[J]. Semin Arthritis Rheum, 2012,41(4) :535-544.
引证文献6
-
1石岩江,申军.桂枝芍药知母汤加减治疗对风寒湿痹型类风湿关节炎患者血清炎症因子和OPG及RANKL水平的影响[J].四川中医,2018,36(12):106-109. 被引量:24
-
2张玉忠.汉防己甲素联合甲氨蝶呤治疗类风湿性关节炎临床疗效及安全性评价[J].中国临床医生杂志,2014,42(9):55-56. 被引量:6
-
3庞金奎,杨秀峰.英夫利西单抗联合甲氨蝶呤治疗活动性类风湿关节炎疗效分析[J].中外医疗,2015,34(6):125-126. 被引量:7
-
4杨文浩,刘宁,袁伟,朱丽媛,舒荣,宋海澄,于萍,崔刘福.类风湿关节炎患者心血管疾病危险因素调查[J].中国医药,2015,10(8):1107-1111. 被引量:5
-
5刘禹全,吕新亮.甲氨蝶呤联合艾拉莫德治疗类风湿关节炎研究进展[J].风湿病与关节炎,2016,5(3):67-69. 被引量:13
-
6徐建萍,郭粉娥,岳晓琳,王佩,周红敏,李俊芳,王卫远,刘曦.甲氨蝶呤、艾拉莫德联合物理疗法对类风湿关节炎患者的疗效及RF、ESR、CRP的影响观察[J].中国医药导刊,2017,19(10):1026-1030. 被引量:18
二级引证文献73
-
1张国英,吉福玲,赵小强,黄玉燕.桂枝芍药知母汤治疗风寒湿痹型膝骨性关节炎发作期急性炎症[J].辽宁中医杂志,2022,49(5):135-138. 被引量:7
-
2万红.未来世纪的显示器:从99年显示器市场预测2000年发展[J].电子测试,2000(5):40-42.
-
3穆红璞,贾香坡.甲氨蝶呤治疗类风湿性关节炎对患者痛觉的影响[J].中外医疗,2015,34(22):140-141. 被引量:1
-
4贺桂泉,朱铁梁,邢国胜.肿瘤坏死因子拮抗剂英夫利昔单抗临床应用研究进展[J].天津药学,2016,28(1):36-42. 被引量:7
-
5黄睿,薛红霞,张宁.英夫利昔单抗治疗类风湿关节炎的临床研究[J].实用药物与临床,2016,19(3):331-334.
-
6慈维苹,潘丽丽,万瑾,廖华,王天.中老年类风湿关节炎患者合并冠状动脉粥样硬化性心脏病的发病风险及相关因素研究[J].中国医药,2016,11(5):629-633. 被引量:11
-
7何伟,苏林冲,冯佳,龚书识,任群,金潘,向阳.肿瘤坏死因子-α抑制剂在类风湿关节炎中的应用[J].湖北民族学院学报(医学版),2016,33(1):72-75. 被引量:6
-
8黄颖,姚血明,唐芳,徐晖,王莹,马武开.艾拉莫德对胶原诱导性关节炎大鼠模型的抗炎作用[J].风湿病与关节炎,2017,6(3):5-7. 被引量:8
-
9白云静,申洪波,姜德训,陈竹.汉防己甲素治疗结缔组织病相关间质性肺疾病临床疗效观察[J].中国医刊,2017,52(3):39-42. 被引量:11
-
10杜娟,郭衍秋,廖华,潘丽丽.不同性别急性冠状动脉综合征合并类风湿关节炎患者冠状动脉病变和心脏结构及功能特点分析[J].中国医药,2017,12(4):491-495. 被引量:4
-
1孙维栋,周建尧,侯韬,赵建治,韩晓伟,王国芳.类风湿关节炎肺间质病变的影响因素及与肺动脉高压关系的探讨[J].浙江医学,2015,37(17):1466-1468.
-
2李熙霞,程德云.COPD和哮喘气道炎症的差异[J].现代临床医学,2007,33(5):386-389. 被引量:5
-
3Iternational ACR Group Committee.类风湿性关节炎的治疗指南[J].继续医学教育,2005,19(3):67-73. 被引量:21
-
4刘建,程佳,苏江,张晶,朱静.类风湿关节炎患者抗环瓜氨酸肽抗体与关节外受累的关系探讨[J].实用医院临床杂志,2008,5(4):73-75. 被引量:2
-
5马锋振,马洪升.幽门螺杆菌相关胃黏膜疾病炎症、凋亡与乳酸杆菌的关系[J].世界华人消化杂志,2006,14(3):312-317. 被引量:11
-
6关琦,于果,张海军.地西他滨联合CAG方案治疗骨髓增生异常综合征的疗效观察[J].检验医学与临床,2015,12(22):3339-3341. 被引量:1
-
7冯媛媛(综述),吕新亮(审校).抗环瓜氨酸肽抗体在类风湿关节炎中的应用[J].医学综述,2009,15(9):1399-1401. 被引量:1
-
8王晓斐,李庆云,万欢英,李敏.OSAHS患者心血管疾病的炎症预报因子[J].上海交通大学学报(医学版),2007,27(7):887-890. 被引量:2
-
9林珺芳,陈君敏,郑玲,薛原,芮红兵.类风湿关节炎患者血清葡萄糖-6-磷酸异构酶检测及分析[J].福建医科大学学报,2010,44(4):284-287.
-
10王战立.45例胆管癌临床诊治分析[J].中国实用医药,2009,4(27):97-98.